Eli Lilly & Co.’s weight-loss shot Zepbound won approval in the US as the first drug to treat sleep apnea, opening the door for broader insurance coverage of the blockbuster medicine.

Eli Lilly gained FDA approval late Friday for its weight-loss drug, Zepbound, as a treatment for obstructive sleep apnea.

The federal government is phasing out off-brand copies of two blockbuster drugs used to treat obesity and diabetes.